Current Editions
Causal biology is the North Star of R&D, from Karuna to ADC engineering, says BMS’s Plenge
Bristol Myers’ head of research leans into CNS, modality innovation, first vs. best in class, and more on The BioCentury Show
Discovery & Translation
Product Development
CDK2 inhibitors at AACR: An answer to CDK4/6 resistance?
AACR abstracts highlight CDK2 inhibition as solution to CDK4/6 resistance and route to reaching more cancer types
Finance
Venture report: Metsera’s $290M launch, Regeneron’s new VC fund
Plus fundings for Asher, Pathios, Outrun and Theolytics
Management Tracks
Domain, Initial among quartet of biotechs unveiling CEOs
Plus: Jim Jenson becomes CEO of Morphoceuticals, and updates from Xeno, NeoGenomics, DeepUll and Verastem
BioCentury ISSN 1097-7201